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Abstract
Aims/hypothesis Individuals with type 2 diabetes have an altered bacterial composition of their gut microbiota compared with
non-diabetic individuals. However, these alterations may be confounded by medication, notably the blood-glucose-lowering
biguanide, metformin.We undertook a clinical trial in healthy and previously drug-free menwith the primary aim of investigating
metformin-induced compositional changes in the non-diabetic state. A secondary aim was to examine whether the pre-treatment
gut microbiota was related to gastrointestinal adverse effects during metformin treatment.
Methods Twenty-seven healthy young Danish men were included in an 18-week one-armed crossover trial consisting of a pre-
intervention period, an intervention period and a post-intervention period, each period lasting 6 weeks. Inclusion criteria were men
of age 18–35 years, BMI between 18.5 kg/m2 and 27.5 kg/m2, HbA1c < 39 mmol/mol (5.7%) and plasma creatinine within the
normal range. No prescribed medication, including antibiotics, for 2 months prior to recruitment were allowed and no previous
gastrointestinal surgery, discounting appendectomy or chronic illness requiring medical treatment. During the intervention the
participants were given metformin up to 1 g twice daily. Participants were examined five times in the fasting state with blood
sampling and recording of gastrointestinal symptoms. Examinations took place at Frederiksberg Hospital, Denmark before and after
the pre-intervention period, halfway through and immediately after the end of intervention and after the wash-out period. Faecal
samples were collected at nine evenly distributed time points, and bacterial DNAwas extracted and subjected to 16S rRNA gene
amplicon sequencing in order to evaluate gut microbiota composition. Subjective gastrointestinal symptoms were reported at each
visit.
Results Data from participants who completed visit 1 (n=23) are included in analyses. For the primary outcome the relative
abundance of 11 bacterial genera significantly changed during the intervention but returned to baseline levels after treatment
cessation. In line with previous reports, we observed a reduced abundance of Intestinibacter spp. andClostridium spp., as well as
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an increased abundance of Escherichia/Shigella spp. and Bilophila wadsworthia. The relative abundance at baseline of 12
bacterial genera predicted self-reported gastrointestinal adverse effects.
Conclusions/interpretation Intake of metformin changes the gut microbiota composition in normoglycaemic young men. The
microbiota changes induced by metformin extend and validate previous reports in individuals with type 2 diabetes. Secondary
analyses suggest that pre-treatment gut microbiota composition may be a determinant for development of gastrointestinal adverse
effects following metformin intake. These results require further investigation and replication in larger prospective studies.
Trial registration Clinicaltrialsregister.eu 2015-000199-86 and ClinicalTrials.gov NCT02546050
Funding This project was funded by Danish Diabetes Association and The Novo Nordisk Foundation




ASV Amplicon sequence variant
PERMANOVA Permutational multivariate ANOVA
RF Random forest
ROC Receiver operating characteristic
VAS Visual analogue scale
Introduction
For decades, the biguanide, metformin, has been the first-line
oral glucose-lowering drug of choice when treating type 2 dia-
betes. The antihyperglycaemic effects of metformin include
suppression of hepatic gluconeogenesis and increased glucose
uptake in skeletal muscle tissue mediated by activation of
adenosine monophosphate-activated protein kinase (AMPK)
[1–3]. Some studies also suggest the involvement of non-
AMPK-mediated suppression of hepatic gluconeogenesis [4,
5]. However, evidence suggests that the gastrointestinal tract
and the microorganisms that reside within it are partly involved
in mediating both beneficial and adverse effects of metformin.
Intraluminal metformin concentration in the gastrointestinal
tract is up to 300 times higher than in plasma [6, 7], and met-
formin treatment decreases intestinal glucose absorption [8].
Furthermore, AMPK activation in duodenal epithelium lowers
the plasma glucose concentration in rats [9]. Individuals with
type 2 diabetes have an altered composition of the gut micro-
biota [10–14], and part of the aberration of the microbiota is
linked to metformin treatment [14–18]. The gut microbiota is
involved in intestinal bile acid metabolism and short-chain fatty
acid production, which could explain some of the glucose-
lowering effect of metformin, through effects on incretin
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secretion, hepatic glucose homeostasis and beta cell function
[19, 20]. In support of this, data from 22 patients with type 2
diabetes, treated with metformin for 3 days, showed a
Bacteroides fragilis-linked increase in the intestinal concentra-
tion of glycoursodeoxycholic bile acid, which in rodent studies
has been associated with improvement of hyperglycaemia [15].
Furthermore, the faecal concentration of the short-chain fatty
acid propionate was increased in 15 metformin users compared
with nine non-users [21]. Similarly, during a 4 month interven-
tion, faecal butyrate and propionate concentrations were in-
creased significantly in men treated with metformin compared
with placebo [18], demonstrating an effect of metformin on
fermentative metabolites involved in regulating human metab-
olism. A hyperglycaemia-independent effect of metformin on
the induced perturbation of the gut microbiota has recently been
shown after 1 week of metformin intake in 18 healthy individ-
uals [16], and elucidation hereon could further our understand-
ing of the link between type 2 diabetes and the gut microbiota.
The most common side effect of metformin treatment is
gastrointestinal discomfort, including nausea, bloating, flatu-
lence and diarrhoea [22, 23]. The mechanisms responsible for
these adverse effects are poorly understood but a role of the
gut microbiota as a potential mediator has been proposed [14].
Whether the side effects commonly associated with metfor-
min treatment arise from changes in the gut microbiota needs
further exploration.
The primary objective of the present intervention in young,
healthy men was to investigate compositional changes of the
gut microbiota following metformin intake, independent of the
physiological changes induced by the diabetic state. In post hoc
analyses, we aimed to explore whether the pre-intervention gut
microbiota profile was related to self-reported gastrointestinal
discomfort following metformin intervention.
Methods
Experimental design and study participants The study was
designed as a non-blinded, non-randomised, one-armed cross-
over study. Participants were studied for 18 weeks, divided
into a run-in period, an intervention period and a wash-out
period, each lasting 6 weeks. During the trial period
(July 2015 to February 2016), participants were examined at
five visits (Fig. 1a) at Frederiksberg Hospital, Denmark.
Participants were eligible for enrolment if they were men,
age 18–35 years, had a BMI between 18.5 kg/m2 and 27.5 kg/
m2, HbA1c < 39 mmol/mol (5.7%) and plasma creatinine
within the normal range. Inclusion criteria included no pre-
scribedmedication, including antibiotics, for 2 months prior to
recruitment, no previous gastrointestinal surgery discounting
appendectomy or chronic illness requiring medical treatment.
Participants were instructed not to change dietary habits and
lifestyle during the study period.
The intervention was initiated after the second visit,
6 weeks after inclusion. All study participants were instructed
to take metformin according to a fixed schedule: 500 mg once
daily for the first week, 500 mg twice daily for the second
week, 1000 mg+ 500 mg daily for the third week and
1000 mg+ 1000 mg daily for the remaining 3 weeks of the
intervention period.
The study was designed for 25 men starting the interven-
tion, expecting a 20% dropout.
The trial was conducted according to the International
Conference on Harmonization’s Good Clinical Practice guide-
lines including the Declaration of Helsinki II. The study was
approved by the Ethical Committees of the Capital Region of
Denmark (protocol ID: H-7-2014-012) and was registered at
www.clinicaltrialsregister.eu (no. 2015-000199-86) and at
ClinicalTrials.gov (NCT02546050). All participants gave
written informed consent before taking part in the study. No
changes to methods were made after trial commencement.
The trial was concluded when all the participants had finalised
their last visit. No serious adverse events were reported during
the trial.
Clinical data Participants underwent clinical examination five
times during the trial: at baseline (visit 1), at the end of the
run-in (week 6; visit 2), 3 weeks into the intervention period
(week 9; visit 3), at the end of the intervention period
(week 12; visit 4) and at the end of the wash-out period
(week 18; visit 5). Gastrointestinal symptoms (overall
abdominal discomfort and degree of abdominal pain, bloating,
constipation, diarrhoea, flatulence, metal taste, nausea and stool
consistency satisfaction) were evaluated at all five visits using a
digital visual analogue scale (VAS) and recorded as an integer
between 0 and 100.
At visits 1, 2, 4 and 5, respectively, participants were ex-
amined with height, weight, hip and waist circumference, BP
and bioimpedance. Detailed information on anthropometrics
can be found in electronic supplementary material (ESM)
Methods. A questionnaire on quality of life, physical activity
and health status was completed at baseline.
Blood samples were collected at all visits after participants
had fasted for 10 h overnight. Alanine aminotransferase and
cobalamin were analysed using an enzymatic slide test, and
creatinine, glucose, cholesterol, HDL cholesterol, and triglyc-
eride were measured using a colorimetric slide test. LDL cho-
lesterol was calculated using the Friedewald formula [24].
HbA1c was measured using liquid chromatography and insu-
lin was measured using immunoassay. Leukocytes and differ-
ential white blood cell count were measured using flow cy-
tometry. Plasmametformin concentration was measured using
high performance liquid chromatography followed by tandem
mass spectrometry to ensure compliance. Detailed informa-
tion on biochemical measurements is presented in the ESM
Methods. HOMA of insulin resistance and beta cell function
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were calculated from fasting plasma concentrations of glucose
and insulin according to Matthews et al [25].
Participants were divided into two groups based on change in
reported overall abdominal discomfort. An increase inVAS score
at visit 3 exceeding 2 × SEM at baseline was considered signif-
icant and used as a cut-off. One participant who dropped out
before visit 3 due to severe gastrointestinal discomfort was count-
ed among thosewho developed gastrointestinal adverse effects in
spite of missing VAS data. By this definition, 10 of 23 partici-
pants experienced an increase in overall abdominal discomfort.
Faecal samples and data processing
Participants were instructed to deliver nine faecal samples
throughout the study period. Samples were collected on the
day of examination if possible and immediately frozen either
at the study site or at home, in which case samples were
transferred to the laboratory on dry ice. Samples were stored
at −80°C until DNA extraction.
A total of 206 faecal samples were collected but two sam-
ples did not contain sufficient material for DNA extraction.
Genomic DNAwas isolated, followed by PCR amplification
of the V4 hypervariable region of the bacterial 16S rRNA
gene and sequencing on an Illumina MiSeq platform generat-
ing a total of 9,466,021 (mean 43,622 [SD 18,700]) paired-
end (250 bp) reads. See ESM Methods for detailed informa-
tion. Twelve samples that failed during the first run were
resequenced. Processing of raw sequencing data was per-
formed using the dada2 (v1.4.0) R package [26]. Following
inspection of quality profiles, denoising, merging of reads and
removal of chimeric sequences, a total of 7,214,117 reads
(mean 34,702 [SD 12,889]; minimum 10,736) in 1764 unique
amplicon sequence variants (ASVs) were available for down-
stream analyses. Taxonomical assignment of ASVs from
kingdom to species was performed against the Silva v128
database, using the dada2 implementation of the naive
Bayesian RDP classifier [27].
Statistical analyses The primary outcome was compositional
change in abundance of ASVs agglomerated at the taxonomic
level of genus. Pre-specified secondary outcomes were as fol-
lows: compositional change in abundance of non-
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Fig. 1 Study design and flow chart. (a) One-armed crossover design with
five visits and a total of nine faecal samplings (F1–F9). Metformin inter-
vention was initiated after visit 2, with a gradual increase in dose over
3 weeks, from 500 mg to 2000 mg, to minimise adverse effects. Blood
samples were drawn at all five visits. Self-reported gastrointestinal symp-
toms were evaluated at all visits using a VAS. Anthropometrics measure-
ments were taken every 6 weeks and plasma metformin was measured
twice during the intervention period to assess compliance. (b) Flowchart
of study. Twenty-nine men underwent screening. Two participants were
ineligible for inclusion. Twenty-seven were included in the trial. Three
participants dropped out during the run-in period: two dropped out im-
mediately after the screening visit and another dropped out immediately
after the first visit, for undisclosed reasons. One participant dropped out
during the intervention due to severe gastrointestinal discomfort. One
participant dropped out during the post-intervention follow-up, for undis-
closed reasons. Twenty-three completed the intervention period, 22 par-
ticipants completed the follow-up and 25 were included in the analyses.
Two participants reduced metformin intake because of side effects. GI,
gastrointestinal; p-metformin, plasma metformin
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quantified by the number of observed ASVs (richness),
Shannon’s entropy and Pielou’s evenness (Shannon’s entro-
py/loge[richness]); change in community structure and mem-
bership quantified by Canberra and Jaccard distances, respec-
tively, and change in anthropometric and biochemical traits.
Post hoc analyses included random forest (RF) classification
of individuals developing gastrointestinal discomfort and test-
ing for bacterial genera and ASVs responding differently to
metformin in these participants, compared with those who did
not develop gastrointestinal side effects. Data from 24 partic-
ipants examined at least once during the intervention period
were included in these subanalyses. Data from participants not
following protocol (e.g. reduced metformin intake, n = 2)
were omitted from analyses from the time they deviated from
protocol. In total, 25 participants completed visit 1 and were
included in the statistical analyses, but one participant dropped
out before initialisation of the intervention.
ASV abundances were agglomerated at genus level using
the phyloseq R package, normalised using total sum scaling,
and log transformed following addition of a pseudocount cor-
responding to the lowest non-zero normalised abundance of
each taxon. Intervention effect was modelled by a one-way
repeated measures ANOVA using mixed linear regression as
implemented in the lme4 R package. Models were fitted using
restricted maximum likelihood using samples from all time
points. The abundance of each genus at each time point during
the metformin intervention was compared by a post hoc t test
with the mean abundance averaged over the three samples
collected during the pre-intervention period. Genera never
present in >80% of participants were excluded from analyses.
Intervention effect on non-agglomerated ASV abundances,
bacterial richness, Shannon’s entropy and Pielou’s evenness
was assessed using the same approach considering a two-
tailed p value <0.05 as significant. Correction for false discov-
ery rate was done for all genera/ASVs across all time points by
the Benjamini–Hochberg method, applying a false discovery
rate of 10% for significance.
Intervention effect on community structure and community
membership was assessed by permutational multivariate
ANOVA (PERMANOVA; vegan R Package v2.4.6) of
Canberra and Jaccard distances, contrasting each intervention
and post-intervention time point to the average across the three
pre-intervention time points. Principal coordinate ordination
was performed using the capscale function of the vegan pack-
age, specifying an unconstrained model.
RF classification was used to identify bacterial genera that
at baseline were discriminative for the development of gastro-
intestinal adverse effects during the intervention. RF models
were trained on total sum scaled abundances of 124 bacterial
genera using the caret (v6.0.79) and randomForest (v4.6.12) R
packages with 25 iterations of bootstrap resampling. Down-
sampling during resampling was applied to address class im-
balance. Performance across resamples was evaluated by the
area under the receiver operating characteristic (ROC) curve
and discriminant genera were ranked by the mean decrease in
accuracy. Using the optimal variable settings from the naive
RF classifier (mtry = 2), we applied the Boruta (v5.2.0) R
package for feature selection of all-relevant discriminant gen-
era identified across 200 repetitions using different random
seeds. Selected genera were subsequently used to build an
optimal RF classifier, as described above.
We used mixed linear regression to identify bacterial gen-
era and ASVs responding differently to the metformin inter-
vention in participants who developed gastrointestinal side
effects compared with those who did not. A response profile
model was specified with a main effect of time (categorical)
and a time × group interaction as fixed effects and a random
intercept for each participant, thereby testing the difference
between groups at all time points during the intervention.
Data were corrected for multiplicity as described above.
Change in clinical and biochemical traits was assessed
using linear mixed model regression ANOVA as outlined
above. Logarithmic transformation of the dependent variable
was applied if deemed appropriate upon inspection of residual
plots and normal probability plots. For VAS data, a constant of
1 was added prior to transformation. Difference in plasma
metformin between visit 3 and 4 were tested with a
Wilcoxon signed-rank test.
All statistical analyses were made using R v3.4.2 (https://
www.R-project.org/).
Results
Study population characteristics Twenty-nine men were
assessed for eligibility, two participants did not meet inclusion
criteria. Two participants dropped out before visit 1 and were
excluded from analyses. One participant discontinued after
visit 1. Twenty-four participants started the intervention with
metformin and 25 participants with relevant data were includ-
ed in analyses (Fig. 1b).
Study population characteristics throughout the trial are
presented in Table 1. Briefly, participants had a mean age of
26 years (SD 3.4), were lean with median BMI of 22.9 kg/m2
(SD 2.1), had a fat percentage of 14.0% (SD 3.3) and were
normoglycaemic with fasting plasma glucose 5.3 mmol/l (SD
0.4) and HbA1c 33.4 mmol/mol (5.2%) (SD 2.9 and 0.26,
respectively) at baseline.
Linear mixed effect modelling revealed a significant in-
crease in body fat percentage (0.98%, p = 0.002) and waist/
hip ratio (0.041, p = 0.002) at visit 5 compared with a com-
bined baseline value of visit 1 and 2. A significant decrease in
HbA1c was detected at visit 3 (−1.15mmol/mol [−0.11%], p =
0.03) and visit 4 (−1.67 mmol/mol [−0.15%], p = 0.001).
There was also a decrease in plasma B12 (−17.20%, p =
0.001) and plasma cholesterol (−0.49 mmol/l, p = 0.007)
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levels at visit 4 and a counter response with significantly ele-
vated levels of these two variables at visit 5 (13.87%, p = 0.03
and 0.40 mmol/l, p = 0.03, respectively).
Metformin changes gut microbiota composition in healthy
adults The primary outcome was compositional changes in
the gut microbiota at genus level. The abundance of five bac-
terial genera was significantly decreased and the abundance of
six was significantly increased during the metformin interven-
tion at a false discovery rate of 10%, at least once during the
intervention period (Fig. 2, ESM Fig. 1 and ESM Table 1). All
returned to baseline levels after treatment cessation. Of the
genera decreasing in abundance, Intestinibacter, Clostridium
(Clostridium sensu stricto 1) and Terrisporobacter decreased
immediately after treatment initiation and remained low
throughout the intervention period. The abundance of
Senegalimassilia decreased immediately after treatment initi-
ation but reverted to baseline at subsequent time points. The
abundance of an unclassified Lachnospiraceae (UCG-010)
genus was unaffected during the first 10 days (F4) (Fig. 1a)
of metformin treatment, decreased 3 weeks (F5) into the in-
tervention after the dose was increased to 1500 mg daily and
then subsequently reverted to baseline levels. Among the bac-
terial genera that increased in abundance, Escherichia/
Shigella increased immediately after treatment initiation (F4)
and remained significantly increased throughout the
intervention period. Likewise, Bilophila increased throughout
the intervention, but this increase was not evident until week 3
(F5) in the intervention. The increase in the abundance of
Lachnoclostridium was nominally significant 3 weeks (F5)
into the intervention period and this increase became signifi-
cant compared with baseline at 4.5 weeks (F6), after which
time this genus began to revert to baseline levels (remaining
increased compared with baseline at nominal significance).
Caproiciproducens showed a nominally significant increase
4.5 weeks after treatment initiation (F6) and became signifi-
cantly increased after 6 weeks of metformin treatment (F7).











n 25 24 23 23 22
Age, years 26 ± 3.4
BMI, kg/m2 22.9 ± 2.1 22.8 ± 2.0 22.8 ± 1.9 22.8 ± 2.0
Body fat, % 14.0 ± 3.3 14.3 ± 3.0 14.4 ± 3.0 14.6 ± 3.3**
Waist/hip ratio 0.88 ± 0.03 0.88 ± 0.04 0.87 ± 0.04 0.90 ± 0.06**
Systolic BP, mmHg 123 ± 11.6 125 ± 9.0 122 ± 7.8 124 ± 7.1
Diastolic BP, mmHg 72 ± 5.5 71 ± 6.8 71 ± 8.9 72 ± 8.4
Fasting plasma glucose, mmol/l 5.3 ± 0.4 5.2 ± 0.3 5.2 ± 0.3 5.2 ± 0.3 5.4 ± 0.5
Fasting serum insulin, pmol/l 42 (32–51) 35 (32–57) 45 (30–57) 35 (25–50) 42 (32–59)
HOMA insulin resistance index 1.61 (1.19–2.11) 1.34 (1.18–2.12) 1.76 (1.11–2.32) 1.32 (0.96–1.92) 1.62 (1.20–2.38)
HOMA beta cell function, % 76 (64–89) 80 (57–106) 87 (65–101) 65 (54–110) 86 (55–105)
HbA1c, mmol/mol 33.4 ± 2.9 33.1 ± 3.0 32.4 ± 2.6* 32.4 ± 2.9** 33.3 ± 2.8
HbA1c, % 5.2 ± 0.26 5.2 ± 0.28 5.1 ± 0.24* 5.1 ± 0.26** 5.2 ± 0.26
Fasting plasma B12 pmol/l 320 (262–408) 327 (264–443) 298 (257–459) 281 (251–389)** 392 (283–437)*
Fasting blood total leucocytes, ×109/l 5.9 ± 1.8 5.7 ± 1.4 5.8 ± 1.3 5.8 ± 1.0 6.0 ± 1.4
Fasting plasma total cholesterol, mmol/l 4.31 ± 0.8 4.41 ± 0.82 4.38 ± 0.90 4.15 ± 0.83** 4.55 ± 0.84*
Fasting plasma metformin, nmol/l 399 (246–507) 449 (292–660)
Data are displayed as mean ± SD or median (interquartile range)
Visits 3, 4 and 5, respectively, were tested vs a combined baseline averaged across visit 1 and 2 using mixed linear regression. Difference in plasma
metformin between visit 3 and 4 was tested with a Wilcoxon signed-rank test
*p < 0.05 and **p < 0.01 vs baseline
Fig. 2 Metformin-responsive bacterial genera exhibiting a change in
relative abundance during the metformin intervention. Boxes represent
interquartile range (IQR), with the inner horizontal line representing the
median. Whiskers represent values within 1.5 × IQR of the first and third
quartiles. Circles represent individual samples with lines connecting
samples from the same individual. The purple band represents the pre-
intervention mean and 95% confidence limits averaged across the three
pre-intervention time points. Diamonds and connecting lines represent
mean values, with yellow and green diamonds, respectively,
representing nominal (p < 0.05) and false discovery rate adjusted (q <
0.05) significant differences from the averaged pre-intervention mean.
The relative abundance at each time point during the intervention was
compared with the averaged pre-intervention mean by linear mixed
model regression ANOVA. Only genera with a significant change at
least at one time point following correction for false discovery rate are
presented
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Tyzzerella (Tyzzerella_3) was increased immediately after
treatment but reverted to baseline at the subsequent time
points. A Prevotella genus (Prevotella_6) increased in abun-
dance with nominal significance after 3 weeks and significant-
ly at 4.5 weeks of treatment (F6) but reverted to baseline
before treatment cessation.
We identified five ASVs that decreased during the inter-
vention, one of which was assigned to Clostridium
(ASV_156), one to Intestinibacter bartlettii (ASV_128), one
to Lachnospiraceae (ASV_247), another to Terrisporobacter
(ASV_239) and one to Peptostreptococcaceae (ASV_80).
Twelve ASVs increased, among which four belonged to the
family Lachnospiraceae, including one assigned to
Lachnoclostridium (ASV_178), one was assigned to
Escherichia/Shigella (ASV_40), another to Alistipes
finegoldii (ASV_94) and one to Bilophila wadsworthia
(ASV_110) (ESM Fig. 1, ESM Table 2).
No uniform effect of metformin on community structure or
diversityWe did not see any effect of metformin treatment on
gut microbiota richness (p = 0.60–0.80), evenness (p = 0.06–
0.99) or diversity (p = 0.08–0.90) at any time point during the
intervention (ESM Fig. 2). Conversely, we found a significant
change in community structure (Canberra distances) at genus
level (R2 = 0.31–0.69%; p = 0.001–0.047) at all time points
during the intervention. The change in community member-
ship (Jaccard distances) was less pronounced and only signif-
icant after 4.5 weeks (R2 = 0.62%; p = 0.003) and 6 weeks
(R2 = 0.43%; p = 0.03) of metformin intervention. However,
principal coordinate ordination analysis demonstrated that the
change during the intervention period did not reflect a uniform
shift, but individual changes in community structure and
membership (ESM Fig. 3).
Pre-intervention gut microbiota associated with gastrointes-
tinal side effects Self-reported measures of gastrointestinal
discomfort are presented in Table 2. Overall, we saw an in-
crease in gastrointestinal discomfort, represented by an in-
crease in the severity of abdominal pain (404% [95% CI 91,
1225]; p = 0.0011), nausea (392% [95% CI 78, 1258]; p =
0.002), bloating (283% [95% CI 31, 1007]; p = 0.01) and di-
arrhoea (261% [95% CI 23, 959]; p = 0.02) and an increase in
overall abdominal discomfort (67% [95% CI 216, 1800];
p < 0.001) at the first visit (3 weeks) after initiation of the
intervention. All side effects diminished towards the end of
the intervention period. There was, however, substantial inter-
individual variation in gastrointestinal adverse effects, with
some individuals developing severe discomfort and others
experiencing only mild side effects or none at all. We
dichotomised the study group based on the change in overall
abdominal discomfort from baseline to the first visit during the
intervention: ten participants who developed abdominal side
effects and 13 who did not (Fig. 3a). When building an RF
classifier on baseline abundances of 124 unselected bacterial
genera, we were able to moderately discriminate between par-
ticipants who developed gastrointestinal side effects and those
who did not, with an area under the ROC curve of 0.70 (95%
CI 0.79, 0.60). Repeated feature selection identified 12 bacte-
rial genera having discriminative importance (Fig. 3b), with
Sutterella, Allisonella, Akkermansia, Bacteroides and
Paraprevotella as the main discriminant genera. By building
an RF classifier based on the baseline abundances of these 12
genera, we were able to distinguish participants who devel-
oped gastrointestinal side effects from those who did not, with
a ROC AUC of 0.90 (95% CI 0.94, 0.87) (Fig. 3c). No bac-
terial genera or ASVs changed differently in the two groups
during the metformin treatment.
Table 2 Self-reported gastrointestinal adverse effects throughout the trial
Adverse effect Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
n 25 24 23 23 22
Overall abdominal discomfort 6.5 (1.6–15.2) 4 (0–9.6) 13.5 (6.5–27.2)*** 7.5 (1–17.5) 0.3 (0–5.9)**
Abdominal pain 0.9 (0–5) 1 (0–8.5) 6.9 (0.6–20)** 0.6 (0–6.5) 0 (0–5.8)
Bloating 3.6 (0–8.4) 2.3 (0.5–6) 5.7 (0.1–26.4)* 6.1 (1.2–18.4)* 0 (0–3.8)
Constipation 0 (0–2.4) 1.5 (0–9.4) 0.6 (0–7.6) 0.5 (0–2.9) 0 (0–3.2)
Diarrhoea 0.1 (0–3.3) 0 (0–4) 0.9 (0–17.6)* 0 (0–15.5) 0 (0–0.6)
Flatulence 6.7 (3–16.7) 6.1 (0.9–14) 11.1 (2.2–27.8) 15.2 (1.6–21.8) 7.7 (0–14.2)
Metallic taste 0.1 (0–1.9) 0 (0–5.9) 0.2 (0–2.4) 0 (0–1.9) 0 (0–0.8)
Nausea 1 (0–3.5) 1.6 (0–7.5) 4.5 (0.1–19.2)** 1 (0–7.9) 0 (0–0.4)
Stool consistency satisfaction 12.8 (0.7–32.3) 9.5 (2.1–25) 24.7 (3–32) 11.3 (3.4–28) 6.4 (0–12.5)
Data are displayed as median (interquartile range)
Symptoms were evaluated using a digital VAS recording severity as an integer from 0 (none at all) to 100 (worst ever). Visits 3, 4 and 5, respectively,
were tested vs a combined baseline averaged across visit 1 and 2 using mixed linear regression
*p < 0.05, **p < 0.01 and ***p < 0.001 vs baseline
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Discussion
We show that metformin intervention has an impact on the
composition of the human gut microbiota at genus and ASV
levels in healthy young men, and these changes are reversed
after discontinuation of metformin. In post hoc, secondary aim
analyses, we demonstrate that the pre-treatment composition
of a subset of bacterial generamay predict risk of development
of gastrointestinal adverse effects to metformin.
Until now, several studies have recognised that metformin
treatment associates with a structural change of the gut microbial
community. A double-blinded randomised study [18] of 40
treatment-naive patients with type 2 diabetes given placebo or
metformin for 4 months showed an increase in abundance of
Escherichia spp. and Bilophila wadsworthia along with a de-
crease in Intestinibacter spp. and Clostridium spp. Similarly,
using shotgun sequencing-based metagenomic analyses we pre-
viously reported an increase of Escherichia spp. and a reduced
abundance of Intestinibacter spp. in metformin-treated type 2
diabetes patients [14]. In a recent study of 18 healthy participants
given 850 mg metformin twice daily for 1 week an increase of
Escherichia/Shigella was also reported [16]. Our analyses of
healthy normoglycaemic individuals similarly showed a reduced
abundance of Intestinibacter spp. and Clostridium spp., as well
as an increased abundance of the genus Escherichia/Shigella and
B. wadsworthia in response tometformin treatment. Collectively,
the findings substantiate that the effect of metformin is indepen-
dent of the dysbiosis induced by diabetes. Additionally, we iden-
tified seven genera changing in abundance during the metformin
intervention, further demonstrating that metformin treatment has
a profound impact on the gut microbiota.
Consistent correlations between alterations of gut microbi-
ota composition and metformin intake, along with evidence
that the intended effect of metformin is possibly co-mediated
by the gut, suggest that alterations of the gut microbiota con-
tribute to the therapeutic effect of metformin. However, long-
term prospective studies of diabetic patients treated with met-
formin could determine causality. Identifying such a causality
could be the first step in performing bacteria-based interven-
tions in type 2 diabetes patients.
Adverse gastrointestinal effects are the primary cause of
failing metformin compliance. In a recent study of 18 healthy
young men exposed to metformin for 1 week, an association
between increased abundance of Escherichia/Shigella spp.
prior to the intervention and later development of gastrointes-
tinal side effects was reported [16]. However, no formal sta-
tistical evidence was provided to substantiate this finding. In
the present study, we aimed to identify genera associated with
development of gastrointestinal adverse effects. The compo-
sition of 12 bacterial genera of the pre-intervention gut micro-
biota was identified as a possible predictor of self-reported
gastrointestinal adverse effects during metformin treatment.
Among these, the highly abundant genera Sutterella,
Akkermansia and Allisonella had the greatest predictive value
[28]. Interestingly, Sutterella spp. have been associated with
infections of the gastrointestinal tract, inflammatory bowel
disease [29] and autism [30].
Akkermansia muciniphila is one of the most abundant bac-
terial species of the human gut microbiota and specialises in
mucin degradation. Using the glycosylated proteins of the epithe-
lial mucus layer as its major source of carbon and nitrogen in
fermentative processes producing the short-chain fatty acids
Fig. 3 Bacterial genera discriminant for development of gastrointestinal
side effects. (a) Participants were divided into two groups based on
change in overall self-reported gastrointestinal side effects measured on
a VAS from baseline to visit 3 (3 weeks into the metformin intervention).
Boxes represent interquartile range (IQR), with the inner horizontal line
representing the median, whiskers representing values within 1.5 × IQR
of the first and third quartiles and circles representing individual samples.
(b) Importance of bacterial genera identified by Boruta feature selection
as being discriminant at baseline for development of gastrointestinal dis-
comfort during metformin intervention. Genera are ordered by mean de-
crease in accuracy from anRFmodel based on baseline abundances of the
12 discriminant genera fitted using bootstrap resampling. (c) ROC curve
representing the ability of the RF model to discriminate between partic-
ipants who develop gastrointestinal discomfort and those who do not. The
shaded area represents the 95% CI; AUC= 0.9
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acetate and propionate,A.muciniphila strengthens the integrity of
the intestinal epithelium and regulates the gut barrier function
[31]. In studies in animals [32] and humans [17, 33], metformin
treatment was associated with increased abundance of
A. muciniphila and the bacterium has been linked to improved
glycaemic control [34]. We did not identify A. muciniphila
among the metformin-responsive bacteria in the present study,
perhaps becausemetformin treatment in individualswith diabetes
resets a perturbation in A. muciniphila abundance caused by the
disease; an imbalance that is not present in healthy individuals.
The genus Allisonella, and the only known species
A. histaminiformans, produces histamine from histidine [35].
Histamine is a potent vasoactive agent causing vasodilatation
and increased vascular permeability, as well as a potent induc-
er of mucus secretion. Histamine is capable of inducing stom-
ach ache, cramps, meteorism and diarrhoea, which are all
known gastrointestinal side effects of metformin treatment
[36]. Interestingly, in vitro studies have shown that metformin
inhibits degradation of histamine by diamine oxidase at con-
centrations achieved in the intestine after therapeutic doses
[37]. Whether metformin affects histamine production by the
gut microbiota, how that may interact with effects on host
capacity for histamine degradation to induce gastrointestinal
intolerance and how the intolerance might be prevented or
treated require testing in future studies. Yet, our findings of
gastrointestinal side effects associated with pre-treatment bac-
terial composition must be interpreted with caution as our
dataset is limited by its size and lack of validation in an inde-
pendent cohort. Furthermore, there is a risk of overestimation
due to small sample size and the large number of features in
the model. Despite this major limitation, our data generate a
hypothesis for future studies aiming to limit gastrointestinal
side effects in patients introduced to metformin bymodulating
intestinal bacterial composition before medication is given.
A strength of the study is that multiple faecal samples were
collected prior to the intervention (three samples over
6 weeks), enabling us to account for background fluctuations
in gut microbiota composition, thereby improving the reliabil-
ity of intra-individual modelling. Longitudinal sampling dur-
ing and after the intervention also demonstrates the dynamics
of the gut microbiota in response to the initiation and cessation
of treatment. The design is, however, underpowered to test
inter-individual effects, which is presumably why we were
unable to identify bacterial genera or ASVs responding differ-
ently to the metformin intervention in participants who devel-
oped or did not develop gastrointestinal side effects. Much
larger sample sizes are required to reliably identify interven-
tional effects in between-group analyses [38]. Other limita-
tions include the lack of blinding and inclusion of a placebo
control group. Technologically, the study was limited by us-
age of the 16S rRNA gene amplicon sequencing approach,
which is well suited for detecting signals at the genus level
but provides limited insight at the species level.
In conclusion, the blood glucose-lowering biguanide met-
formin changes the composition of the intestinal microbiota
independent of the prevailing blood glucose level, showing
that the effect is independent of the dysbiosis induced by di-
abetes. We propose that the pre-treatment composition of a
subset of bacterial genera in the gut may predict risk of gas-
trointestinal side effects, hinting at the potential involvement
of bacterial fermentation, gut barrier function and histamine in
metformin intolerance.
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